RARECast

Ein Podcast von RARECast - Donnerstags

Donnerstags

Kategorien:

512 Folgen

  1. aTyr Pharma Seeks to Modulate Activity in FSHD and Other Rare Disease

    Vom: 28.6.2017
  2. Summit Pursues A Different Approach to Treating Duchenne

    Vom: 21.6.2017
  3. Delivering Enzyme Replacement Therapies Across the Blood-Brain Barrier

    Vom: 14.6.2017
  4. Sangamo Advances Gene Editing Therapies for Multiple Rare Diseases into the Clinic

    Vom: 7.6.2017
  5. Navigating the Challenges of Rare Disease Drug Development

    Vom: 31.5.2017
  6. Accelerating Rare Disease Drug Discovery

    Vom: 24.5.2017
  7. Experimental Rare Disease Therapy Wins New FDA Reg Med Designation

    Vom: 17.5.2017
  8. How Rare Disease Patients Can Get their Voices Heard in Drug Discovery and Development

    Vom: 10.5.2017
  9. One Patient's Difficult Road to a Rare Diagnosis

    Vom: 3.5.2017
  10. How Researchers Diagnosed Four Patients with a Never-Before-Identified Rare Disease in a Day

    Vom: 26.4.2017
  11. Stem Cell Gene Therapy Restores Immune System in Kids with SCID

    Vom: 19.4.2017
  12. Rare Disease Advocates Push for Incentives to Drugmakers Pulled from Cures Act

    Vom: 12.4.2017
  13. Non-Profit Drug Company Seeks to Advance Rare Disease Therapies

    Vom: 5.4.2017
  14. Innovative Collaboration Model Drives Treatment for Rare Disease

    Vom: 29.3.2017
  15. Girl with Rare Disease Inspires Search for Bone Marrow Donors

    Vom: 22.3.2017
  16. A Quest for Tribe: Searching for Others with the Same Ultra-Rare Mutation

    Vom: 15.3.2017
  17. Raising Awareness in a Town with a History of a Rare Disease

    Vom: 8.3.2017
  18. Helping Rare Disease Patients Navigate the World of Information

    Vom: 1.3.2017
  19. Overcoming the Challenges of Rare Disease Drug Development

    Vom: 22.2.2017
  20. Moving Rare Disease Therapies from Hope to Reality

    Vom: 15.2.2017

20 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site